TR199800156T1 - �ok d���k dozlu ila�lar� kat� dozaj �ekillerinde haz�rlama prosesi. - Google Patents
�ok d���k dozlu ila�lar� kat� dozaj �ekillerinde haz�rlama prosesi.Info
- Publication number
- TR199800156T1 TR199800156T1 TR1998/00156T TR9800156T TR199800156T1 TR 199800156 T1 TR199800156 T1 TR 199800156T1 TR 1998/00156 T TR1998/00156 T TR 1998/00156T TR 9800156 T TR9800156 T TR 9800156T TR 199800156 T1 TR199800156 T1 TR 199800156T1
- Authority
- TR
- Turkey
- Prior art keywords
- dose
- low
- dosage forms
- preparation process
- drugs
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title 1
- 229940127021 low-dose drug Drugs 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000013583 drug formulation Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- -1 methoximino Chemical group 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9515624.6A GB9515624D0 (en) | 1995-07-29 | 1995-07-29 | Novel process |
| GBGB9606684.0A GB9606684D0 (en) | 1996-03-29 | 1996-03-29 | Novel process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR199800156T1 true TR199800156T1 (xx) | 1998-04-21 |
Family
ID=26307485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR1998/00156T TR199800156T1 (xx) | 1995-07-29 | 1996-07-29 | �ok d���k dozlu ila�lar� kat� dozaj �ekillerinde haz�rlama prosesi. |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP0841902A2 (cs) |
| JP (1) | JPH11510493A (cs) |
| KR (1) | KR19990035972A (cs) |
| CN (1) | CN1196677A (cs) |
| AP (1) | AP858A (cs) |
| AR (1) | AR004178A1 (cs) |
| AU (1) | AU716961B2 (cs) |
| BG (1) | BG102266A (cs) |
| BR (1) | BR9609804A (cs) |
| CA (1) | CA2228048A1 (cs) |
| CZ (1) | CZ24798A3 (cs) |
| DZ (1) | DZ2077A1 (cs) |
| EA (2) | EA199901055A1 (cs) |
| HU (1) | HUP9900521A3 (cs) |
| IL (1) | IL122897A0 (cs) |
| MA (1) | MA23953A1 (cs) |
| MX (1) | MX9800809A (cs) |
| NO (1) | NO980384L (cs) |
| NZ (1) | NZ315632A (cs) |
| OA (1) | OA10659A (cs) |
| PL (1) | PL325242A1 (cs) |
| SK (1) | SK11098A3 (cs) |
| TR (1) | TR199800156T1 (cs) |
| UY (1) | UY24297A1 (cs) |
| WO (1) | WO1997004750A2 (cs) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9619074D0 (en) * | 1996-09-12 | 1996-10-23 | Smithkline Beecham Plc | Composition |
| JP2002506031A (ja) | 1998-03-11 | 2002-02-26 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 組成物 |
| FR2796840B1 (fr) * | 1999-07-26 | 2003-06-20 | Ethypharm Lab Prod Ethiques | Comprimes faiblement doses et procede de preparation |
| DE60139087D1 (de) | 2000-12-14 | 2009-08-06 | Ortho Mcneil Janssen Pharm | Verfahren zu Herstellung von Zubereitungen enthaltend einen Steroidhormon und ein Stabilisierungsmittel in nicht-kristallinen Form |
| WO2005097076A2 (en) * | 2004-04-09 | 2005-10-20 | Smithkline Beecham Corporation | Low dose pharmaceutical products |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4489026A (en) * | 1982-09-07 | 1984-12-18 | The Upjohn Company | Process for preparing solid unit dosage forms of ultra-low dose drugs |
| JPS5970614A (ja) * | 1982-10-14 | 1984-04-21 | Asahi Chem Ind Co Ltd | 微量主薬系湿式固形製剤方法 |
| US4898736A (en) * | 1988-03-09 | 1990-02-06 | Merck & Co., Inc. | Method for tablet preparation |
| ATE269330T1 (de) * | 1989-04-13 | 2004-07-15 | Beecham Group Plc | Chemische verbindungen |
| ZA939565B (en) * | 1993-12-21 | 1994-08-11 | Applied Analytical Ind Inc | Method for preparing low dose pharmaceutical products. |
-
1996
- 1996-07-25 AR ARP960103748A patent/AR004178A1/es not_active Application Discontinuation
- 1996-07-26 MA MA24329A patent/MA23953A1/fr unknown
- 1996-07-26 UY UY24297A patent/UY24297A1/es not_active IP Right Cessation
- 1996-07-27 DZ DZ960121A patent/DZ2077A1/fr active
- 1996-07-29 SK SK110-98A patent/SK11098A3/sk unknown
- 1996-07-29 PL PL96325242A patent/PL325242A1/xx unknown
- 1996-07-29 NZ NZ315632A patent/NZ315632A/xx unknown
- 1996-07-29 JP JP9507243A patent/JPH11510493A/ja active Pending
- 1996-07-29 MX MX9800809A patent/MX9800809A/es unknown
- 1996-07-29 CN CN96197054A patent/CN1196677A/zh active Pending
- 1996-07-29 EA EA199901055A patent/EA199901055A1/ru unknown
- 1996-07-29 WO PCT/EP1996/003326 patent/WO1997004750A2/en not_active Ceased
- 1996-07-29 AP APAP/P/1998/001170A patent/AP858A/en active
- 1996-07-29 AU AU67384/96A patent/AU716961B2/en not_active Ceased
- 1996-07-29 BR BR9609804A patent/BR9609804A/pt not_active Application Discontinuation
- 1996-07-29 CA CA002228048A patent/CA2228048A1/en not_active Abandoned
- 1996-07-29 KR KR1019980700633A patent/KR19990035972A/ko not_active Ceased
- 1996-07-29 EA EA199800179A patent/EA000740B1/ru not_active IP Right Cessation
- 1996-07-29 HU HU9900521A patent/HUP9900521A3/hu unknown
- 1996-07-29 TR TR1998/00156T patent/TR199800156T1/xx unknown
- 1996-07-29 IL IL12289796A patent/IL122897A0/xx unknown
- 1996-07-29 CZ CZ98247A patent/CZ24798A3/cs unknown
- 1996-07-29 EP EP96927621A patent/EP0841902A2/en not_active Withdrawn
-
1998
- 1998-01-28 OA OA9800013A patent/OA10659A/en unknown
- 1998-01-28 NO NO980384A patent/NO980384L/no unknown
- 1998-02-20 BG BG102266A patent/BG102266A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY24297A1 (es) | 1997-01-23 |
| PL325242A1 (en) | 1998-07-06 |
| EA000740B1 (ru) | 2000-02-28 |
| CA2228048A1 (en) | 1997-02-13 |
| AP858A (en) | 2000-07-12 |
| NO980384L (no) | 1998-03-26 |
| EA199800179A1 (ru) | 1998-10-29 |
| SK11098A3 (en) | 1998-07-08 |
| CZ24798A3 (cs) | 1998-06-17 |
| MA23953A1 (fr) | 1997-04-01 |
| OA10659A (en) | 2002-09-18 |
| WO1997004750A2 (en) | 1997-02-13 |
| MX9800809A (es) | 1998-04-30 |
| AP9801170A0 (en) | 1998-01-31 |
| KR19990035972A (ko) | 1999-05-25 |
| NZ315632A (en) | 1999-11-29 |
| HUP9900521A2 (hu) | 1999-06-28 |
| NO980384D0 (no) | 1998-01-28 |
| EA199901055A1 (ru) | 2000-06-26 |
| EP0841902A2 (en) | 1998-05-20 |
| AU6738496A (en) | 1997-02-26 |
| DZ2077A1 (fr) | 2002-07-22 |
| JPH11510493A (ja) | 1999-09-14 |
| AU716961B2 (en) | 2000-03-09 |
| HUP9900521A3 (en) | 2001-04-28 |
| BR9609804A (pt) | 1999-07-06 |
| IL122897A0 (en) | 1998-08-16 |
| AR004178A1 (es) | 1998-11-04 |
| BG102266A (en) | 1998-10-30 |
| CN1196677A (zh) | 1998-10-21 |
| WO1997004750A3 (en) | 1997-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK48392A (en) | Drug particles having constant release and immediate release | |
| NZ508526A (en) | Opioid formulations for treating pain | |
| WO2001019337A3 (en) | Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing | |
| MY118371A (en) | Tetrahydrolipstatin containing compositions | |
| LV10684B (en) | Controlled release preparation containing a salt of morphine | |
| EP1243267A3 (en) | Amoxycillin and clavulanate containing pharmaceutical formulation | |
| Nielsen et al. | Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group | |
| IL135235A0 (en) | Method and composition for preventing nephrotoxicity caused by cyclosporins and tacrolimus | |
| TR199800156T1 (xx) | �ok d���k dozlu ila�lar� kat� dozaj �ekillerinde haz�rlama prosesi. | |
| PT891186E (pt) | Administração nasal de agentes para o tratamento de emese tardia | |
| ES2179729A1 (es) | Forma farmaceutica solida de administracion oral dispersable en agua, que comprende rifampicina, isoniazida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica. | |
| ES2184561A1 (es) | Forma farmaceutica solida de administracion oral dispersable en agua para el tratamiento de la tuberculosis conteniendo refampicina, isoniazida, pirazinamida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica. | |
| EP0271151A3 (en) | Azumolene dosage form | |
| Maisano et al. | Efficacy of two oral dose regimens of granisetron | |
| Stern et al. | Nifedipine plasma concentration in patients treated for angina pectoris | |
| ATE85218T1 (de) | Oral anzuwendende arzneiform zur einmal taeglichen behandlung der hypertonie mit diltiazemhydrochlorid. | |
| Bickel et al. | Triple buprenorphine maintenance doses maintain opioid-dependent outpatients for 72 hours with minimal withdrawal | |
| Jonsson | Development of long-acting nitrate delivery systems | |
| GB9917290D0 (en) | Pharmaceutical composition | |
| ATE240097T1 (de) | Pharmaceutische zusammensetzung enthaltend (+)- ephedrin und einen h1 rezeptor antagonisten | |
| Lavický et al. | Vibration stress and pharmacokinetics of rifampicin | |
| Ellison Jr et al. | A study in the management of anxiety with lorazepam | |
| Bickel et al. | Triple buprenorphine maintenance doses maintain opioid-dependent outpatients for 72 hours with minimal withdrawal | |
| ECSP961835A (es) | Nuevo procedimiento | |
| Feuerstein et al. | Single drug therapy with sodium valproate in primary generalized epilepsy. Phase 2: Long term efficacy and tolerance study. |